CJC-1295 No DAC vs Tesamorelin
Both compounds are synthetic analogues of growth-hormone-releasing hormone (GHRH) that engage the GHRH receptor on pituitary somatotrophs to stimulate growth-hormone release. They differ in structural modifications, plasma persistence, clinical evidence base, and regulatory status. This page summarises how the published pharmacology and clinical data distinguish them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Modified GHRH(1-29) analogue with four amino acid substitutions for protease resistance (also written MOD GRF 1-29) | Modified GHRH(1-44) analogue with a trans-3-hexenoic acid modification at the N-terminus |
| Receptor target | GHRH receptor on pituitary somatotrophs | GHRH receptor on pituitary somatotrophs |
| Approximate molecular weight | 3367.9 g/mol | 5135.9 g/mol |
| Plasma half-life | Approximately 30 minutes; produces pulsatile GH release pattern | Approximately 26-38 minutes; produces pulsatile GH release pattern |
| Clinical evidence base | Preclinical and research-community pharmacology; no large-scale Phase 3 trials | FDA approved for HIV-associated lipodystrophy; Phase 3 randomised controlled trials published |
| Regulatory status | Not approved as a therapeutic | FDA approved for reduction of excess abdominal fat in HIV patients with lipodystrophy |
| Common research administration route | Subcutaneous injection | Subcutaneous injection |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
CJC-1295 No DAC is a modified GHRH(1-29) analogue that retains the first 29 amino acids of endogenous growth-hormone-releasing hormone with four amino acid substitutions conferring protease resistance. The compound engages the GHRH receptor on pituitary somatotrophs and drives a pulsatile growth-hormone release pattern. The ‘No DAC’ designation indicates the absence of the drug affinity complex (a maleimide-lysine linker for covalent albumin binding) present in the longer-acting DAC-bearing CJC-1295 variant.
Tesamorelin is a modified GHRH(1-44) analogue that retains the full native 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification confers protease resistance while preserving the pulsatile GH-release profile. The compound engages the same GHRH receptor as CJC-1295 No DAC, and the downstream GH-release kinetics are similar in both cases: pulsatile rather than sustained.
The principal distinction is structural length (29 versus 44 amino acids), the nature of the protease-resistance modification (four amino acid substitutions versus N-terminal hexenoic-acid capping), and clinical development history. Tesamorelin has been tested in large-scale Phase 3 trials and received FDA approval for HIV-associated lipodystrophy. CJC-1295 No DAC is widely used in the research-community context but has not been taken through Phase 3 development.
How research has examined each
The CJC-1295 literature (DAC and No DAC variants combined) includes the Teichman pharmacokinetic characterisation showing prolonged GH and IGF-I stimulation with the DAC-bearing variant, the Ionescu study demonstrating pulsatile GH secretion persisting during continuous CJC-1295 stimulation, and detection-methodology studies. The No-DAC variant specifically is used extensively in the research community in combination with ghrelin-receptor agonists, but compound-specific clinical-trial data for the No-DAC variant are limited.
The tesamorelin clinical literature includes multiple Phase 3 randomised controlled trials in HIV-associated lipodystrophy (Falutz et al., NEJM 2007; pooled analysis 2010), long-term safety data, and studies on visceral-fat-associated metabolic outcomes including liver enzymes, inflammatory markers, hepatic transcriptomics, and neurocognitive endpoints. The clinical dataset positions tesamorelin as the most clinically validated GHRH analogue in the published literature.
Both compounds share the GHRH-receptor target and the pulsatile-GH-release profile, but they occupy different positions on the evidence spectrum. Tesamorelin is a clinically validated, FDA-approved compound. CJC-1295 No DAC is a research-community tool compound without large-scale clinical confirmation. Researchers selecting between them for protocol design weigh the clinical validation of tesamorelin against the research-community familiarity and combined-protocol conventions surrounding CJC-1295 No DAC.
Stacking considerations in research contexts
Co-administration of CJC-1295 No DAC and tesamorelin is not described in the published literature. Both engage the same GHRH receptor, so combined dosing would produce receptor-level overlap and dose-response collisions on GH-release endpoints. Researchers typically choose one GHRH analogue per protocol design. Both compounds are sold as separate 10 mg lyophilised vials in the Ronin catalog for independent sourcing.
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as 10 mg lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The CJC-1295 No DAC vial page and the tesamorelin vial page carry per-compound spec sheets, reconstitution math, and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Do both compounds target the same receptor?
Yes. Both are GHRH-receptor agonists that stimulate pulsatile growth-hormone release from pituitary somatotrophs. They differ in structural length, protease-resistance modification, and clinical development history.
Why is tesamorelin FDA-approved and CJC-1295 No DAC not?
Tesamorelin was taken through Phase 3 randomised controlled trials in HIV-associated lipodystrophy and received FDA approval for that indication. CJC-1295 No DAC has not been advanced through Phase 3 development despite extensive use in the research community.
Can they be co-administered?
Not in published protocols. Both engage the same GHRH receptor, so combined dosing would produce receptor-level overlap. Researchers typically select one GHRH analogue per protocol.
Do they share storage and reconstitution practice?
Yes. Both are lyophilised peptides in glass vials, reconstituted in bacteriostatic water, and stored refrigerated at 2-8 °C protected from light.
Are either approved for human use under the Ronin brand?
No. Tesamorelin is FDA-approved under a separate brand name for HIV-associated lipodystrophy. CJC-1295 No DAC is not approved as a therapeutic. Both Ronin vials are research-grade reagents for laboratory use only.
References
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 17018654]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. [PMID 18057338]
- Falutz J et al. Effects of tesamorelin on visceral fat and metabolic markers in HIV. Journal of Acquired Immune Deficiency Syndromes, 2010. [PMID 20101189]
- Fourman LT et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS, 2017. [PMID 28832410]
- Fourman LT et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020. [PMID 32701508]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.